16.93

0.36% -0.09

Intellia Therapeutics Inc (NTLA)

Overview News Price History Option Chain Financials Discussions Forecast

Intellia Therapeutics Inc stock is traded at $16.93, with a volume of 561.64K. It is down -0.36% in the last 24 hours and up +30.18% over the past month. Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Previous Close:

$16.84

Open:

$16.59

24h Volume:

561.64K

Relative Volume:

0.09

Market Cap:

$2.36B

Revenue:

$67.67M

Net Income/Loss:

$-412.69M

P/E Ratio:

-4.4243

EPS:

-3.8266

Net Cash Flow:

$-395.87M

1W Performance:

-4.44%

1M Performance:

+30.18%

6M Performance:

+61.66%

1Y Performance:

+38.33%

1-Day Range:

$16.58

$17.06

1-Week Range:

$16.17

$18.11

52-Week Range:

$7.95

$28.25

Intellia Therapeutics Inc Stock (NTLA) Company Profile

Name

Intellia Therapeutics Inc

Sector

Healthcare (1098)

Industry

Biotechnology (614)

Phone

857-285-6200

Address

40 ERIE STREET, CAMBRIDGE, MA

Employee

377

Twitter

@intelliatweets

Next Earnings Date

2026-08-06

Latest SEC Filings

NTLA's Discussions on Twitter

Compare NTLA vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NTLA Intellia Therapeutics Inc	16.92	2.35B	67.67M	-412.69M	-395.87M	-3.8266
VRTX Vertex Pharmaceuticals Inc	499.80	126.50B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	666.90	69.50B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	923.07	56.92B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	364.50	43.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	191.41	40.34B	742.00K	-1.37B	-1.07B	-7.0731

Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-02-26	Upgrade	William Blair	Mkt Perform → Outperform
Nov-12-25	Downgrade	Wolfe Research	Outperform → Peer Perform
Nov-11-25	Downgrade	Evercore ISI	Outperform → In-line
Nov-07-25	Downgrade	JP Morgan	Neutral → Underweight
Oct-28-25	Downgrade	Bernstein	Outperform → Mkt Perform
Oct-28-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Oct-27-25	Downgrade	Guggenheim	Buy → Neutral
Oct-27-25	Downgrade	William Blair	Outperform → Mkt Perform
Oct-06-25	Upgrade	Citizens JMP	Mkt Perform → Mkt Outperform
Apr-21-25	Upgrade	Wolfe Research	Peer Perform → Outperform
Mar-05-25	Initiated	H.C. Wainwright	Buy
Feb-28-25	Downgrade	Goldman	Neutral → Sell
Feb-28-25	Downgrade	JP Morgan	Overweight → Neutral
Jan-27-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Feb-23-24	Downgrade	Goldman	Buy → Neutral
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Apr-13-23	Initiated	Canaccord Genuity	Buy
Mar-21-23	Initiated	Bernstein	Outperform
Mar-14-23	Upgrade	BMO Capital Markets	Market Perform → Outperform
Feb-01-23	Initiated	Cantor Fitzgerald	Overweight
Jan-24-23	Upgrade	Citigroup	Sell → Neutral
Jan-19-23	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Oct-11-22	Initiated	Morgan Stanley	Overweight
Sep-21-22	Initiated	JP Morgan	Overweight
Sep-01-22	Initiated	Citigroup	Sell
Jun-17-22	Initiated	BMO Capital Markets	Market Perform
Jun-16-22	Initiated	BofA Securities	Buy
Apr-28-22	Initiated	Credit Suisse	Outperform
Feb-18-22	Initiated	William Blair	Outperform
Feb-07-22	Upgrade	Oppenheimer	Perform → Outperform
Jan-31-22	Initiated	Cowen	Outperform
Jan-07-22	Initiated	Piper Sandler	Overweight
Oct-05-21	Initiated	Guggenheim	Buy
Sep-24-21	Initiated	Stifel	Buy
Jun-28-21	Reiterated	H.C. Wainwright	Buy
Jun-11-21	Initiated	H.C. Wainwright	Buy
May-07-21	Upgrade	ROTH Capital	Neutral → Buy
May-04-21	Initiated	RBC Capital Mkts	Outperform
Mar-04-21	Initiated	JMP Securities	Mkt Outperform
Dec-22-20	Downgrade	Robert W. Baird	Outperform → Neutral
Oct-27-20	Initiated	Truist	Buy
Oct-14-20	Initiated	Wells Fargo	Overweight
Sep-18-20	Initiated	Goldman	Buy
Feb-28-20	Upgrade	Oppenheimer	Perform → Outperform
Feb-14-20	Downgrade	Wedbush	Outperform → Neutral
Nov-01-19	Upgrade	Raymond James	Mkt Perform → Outperform
Jul-09-19	Initiated	Robert W. Baird	Outperform
Jun-10-19	Initiated	ROTH Capital	Neutral
May-03-19	Upgrade	Wedbush	Neutral → Outperform
Apr-12-19	Initiated	Evercore ISI	Outperform
Nov-02-18	Downgrade	Wedbush	Outperform → Neutral
Oct-29-18	Initiated	Credit Suisse	Neutral
Sep-21-18	Initiated	Raymond James	Mkt Perform
May-15-18	Upgrade	Chardan Capital Markets	Neutral → Buy
Mar-08-18	Initiated	JMP Securities	Mkt Outperform
Nov-01-17	Reiterated	Jefferies	Buy
Jun-22-17	Resumed	Jefferies	Buy
Mar-28-17	Initiated	Chardan Capital Markets	Buy
Aug-05-16	Upgrade	Jefferies	Hold → Buy

View All

Intellia Therapeutics Inc Stock (NTLA) Latest News

Jul 08, 2026

(NTLA) Movement as an Input in Quant Signal Sets - Stock Traders Daily

Jul 08, 2026

NTLA Stock Rockets After Hours Before Critical Data For Genetic Disorder Therapy - Stocktwits

Jul 08, 2026

NTLA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI

Jul 08, 2026

A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics - Yahoo Finance

Jul 08, 2026

Jul 07, 2026

Price to earnings forward of Intellia Therapeutics, Inc. – LS:A2AG6H - TradingView

Jul 07, 2026

Jul 06, 2026

Intellia Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Dulac Edward J III - Moomoo

Jul 06, 2026

Intellia CFO Edward Dulac III sells $84,186 in stock By Investing.com - Investing.com Nigeria

Jul 06, 2026

Intellia CFO Edward Dulac III sells $84,186 in stock - Investing.com

Jul 06, 2026

Form 4 Intellia Therapeutics Inc For: 6 July By Investing.com - Investing.com Nigeria

Jul 06, 2026

Intellia Therapeutics (NTLA) VP sells shares to cover RSU tax - Stock Titan

Jul 06, 2026

Intellia (NTLA) CFO’s 4,677-share sale executed under 10b5-1 plan - Stock Titan

Jul 06, 2026

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jul 06, 2026

Intellia lures 13 new employees with 53,250 stock awards - Stock Titan

Jul 06, 2026

Jul 05, 2026

More NTLA, Less RKLB: Cathie Wood’s Latest ARK Trades Explained - Stocktwits

Jul 05, 2026

NTLA Jumps Premarket On Positive Late-Stage Trial Data For Gene-Editing Therapy — Retail Says Buy Now Before It’s Too Late - Stocktwits

Jul 05, 2026

NTLAIntellia Therapeutics Inc Forecast, Target Price - Finviz

Jul 05, 2026

Jul 04, 2026

Investor Alert: Robbins LLP Informs Stockholders of the Intellia Therapeutics, Inc. Class Action - GuruFocus

Jul 04, 2026

Jul 03, 2026

Is Intellia Therapeutics, Inc. (NTLA) A Good Stock To Buy Now? - Yahoo Finance

Jul 03, 2026

Jul 02, 2026

Intellia Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo

Jul 02, 2026

NTLA Stock Price Prediction 2025-2026 | Intellia Therapeutics Inc Forecast - 24/7 Wall St.

Jul 02, 2026

[144] Intellia Therapeutics, Inc. SEC Filing - Stock Titan

Jul 02, 2026

Jul 01, 2026

Wall Street Thinks This High-Flying Biotech Stock Can Soar Another 57% - The Globe and Mail

Jul 01, 2026

Investor Sentiment Divided in Healthcare Sector: Intellia Therap - GuruFocus

Jul 01, 2026

Intellia Therapeutics (NASDAQ:NTLA): Can Innovation Justify the Buzz? - Kalkine Media

Jul 01, 2026

Jun 28, 2026

Price to book forward of Intellia Therapeutics, Inc. – NASDAQ:NTLA - TradingView

Jun 28, 2026

Price to earnings forward of Intellia Therapeutics, Inc. – DUS:38I - TradingView

Jun 28, 2026

Price to book forward of Intellia Therapeutics, Inc. – DUS:38I - TradingView

Jun 28, 2026

Enterprise value to revenue forward of Intellia Therapeutics, Inc. – NASDAQ:NTLA - TradingView

Jun 28, 2026

Enterprise value to revenue forward of Intellia Therapeutics, Inc. – DUS:38I - TradingView

Jun 28, 2026

Price to sales forward of Intellia Therapeutics, Inc. – DUS:38I - TradingView

Jun 28, 2026

Enterprise value to EBIT forward of Intellia Therapeutics, Inc. – NASDAQ:NTLA - TradingView

Jun 28, 2026

Price to sales forward of Intellia Therapeutics, Inc. – NASDAQ:NTLA - TradingView

Jun 28, 2026

Enterprise value to EBITDA forward of Intellia Therapeutics, Inc. – NASDAQ:NTLA - TradingView

Jun 28, 2026

Jun 27, 2026

Liquidity Mapping Around (NTLA) Price Events - Stock Traders Daily

Jun 27, 2026

Certain Stock Options of Intellia Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 28-JUN-2026. - marketscreener.com

Jun 27, 2026

Price to earnings forward of Intellia Therapeutics, Inc. – BOATS:NTLA - TradingView

Jun 27, 2026

NTLA Stock Surges 35% Overnight: Retail Mood Peaks Ahead Of First-Ever Phase 3 Readout For Gene-Editing Therapy - Stocktwits

Jun 27, 2026

Levi & Korsinsky Notifies Shareholders of Intellia Therapeutics - The National Law Review

Jun 27, 2026

Investors who Lost Money on Intellia Therapeutics, Inc. (NTLA) Sh - The National Law Review

Jun 27, 2026